Clarity Pharmaceuticals Ltd (ASX: CU6)
Health Care · Pharmaceuticals · AU
AU$2.48
-5.70% today · -32.1% 1Y
Clarity Pharmaceuticals Ltd (ASX: CU6) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $663.21M and employs 88 people.
Over the last twelve months the share price has lost 32.1%, trading between 1.80 and 5.87.
Tweenvest scores Clarity Pharmaceuticals Ltd across four factors: quality 27/100, value 39/100. Its strongest factor is value.
CU6 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $663.21M
- Revenue (TTM)
- $7.06M
- P/E
- —
- EPS
- -0.28
- Dividend yield
- —
- Beta (5Y)
- 1.18
- 52-week high
- AU$5.87
- 52-week low
- AU$1.80
- Avg volume (3M)
- —
- Shares outstanding
- 373.08M
- Employees
- 88
- Next earnings
- —
About Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company’s lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
- Founded
- 2010
- Listed since
- Aug 25, 2021
- Exchange
- Australian Securities Exchange
- Currency
- AUD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.